Trioxane Thioacetals for Single-Dose Malaria Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for malaria, particularly with artemisinin combination therapy, require multiple doses and face challenges with patient compliance and drug resistance, necessitating a more effective and convenient single-dose oral cure.

Innovation Solution

Development of monomeric and dimeric trioxane thioacetals, which can be used alone or in combination with traditional antimalarial drugs, to treat malaria and other parasitic infections, including toxoplasmosis and cancer, by administering compounds of specific formulas that optimize bioavailability and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If artemisinin combination therapy is used to treat malaria, then treatment efficacy is improved, but patient compliance deteriorates due to multiple doses required

Engineering Contradiction:

Improvetreatment efficacyVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent combines artemisinin with a parasiticidal amine in a single fixed-dose combination tablet, allowing both drugs to be administered together in one dose rather than requiring separate administrations. This merging of drugs into one formulation maintains the synergistic therapeutic effect while simplifying the dosing regimen to improve patient compliance

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The fixed-dose combination tablet serves multiple functions simultaneously: it provides both artemisinin's rapid antiparasitic action and the amine's sustained effect, acts as a single dosing unit, and eliminates the need for separate drug administrations. This multi-functionality in a single formulation addresses both efficacy and compliance requirements

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If repeated dose regimen is used for malaria treatment, then treatment completeness is improved, but treatment duration increases

Engineering Contradiction:

Improvetreatment completenessVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The parasiticidal amine component provides sustained antimalarial activity that continues to act against residual parasites after the initial artemisinin knockdown. This continuous action ensures complete treatment without requiring multiple separate doses, maintaining treatment completeness while reducing the overall treatment duration to a single administration

Inventive Principle:

Principle #20Continuity of useful action

3Ease of operation

If traditional antimalarial drugs are used, then ease of administration is improved, but drug resistance develops

Engineering Contradiction:

Improveease of administrationVSAvoiddrug efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The fixed-dose combination creates a composite therapeutic regimen where artemisinin and parasiticidal amine work synergistically. The amine component specifically addresses resistance issues by targeting different metabolic pathways in the parasite, ensuring that resistance to one drug does not compromise overall treatment efficacy while maintaining ease of oral administration

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS9611273B2Trioxane thioacetal monomers and dimers and methods of use thereof

Publication Date: 2017.04.04 JOHNS HOPKINS UNIVERSITY

AI summary

Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.